For The Latest Medical News, Health News, Research News, COVID-19 News, Pharma News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Thailand Cannabis News, Cancer News, Doctor News, Thailand Hospital News, Oral Cancer News, Thailand Doctors

BREAKING NEWS
Source: Sanofi  Apr 27, 2019  6 years, 8 months, 4 days, 9 hours, 2 minutes ago

Anti-skin cancer drug approved in EU

Presented by
Anti-skin cancer drug approved in EU
Source: Sanofi  Apr 27, 2019  6 years, 8 months, 4 days, 9 hours, 2 minutes ago
French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU. The drug, also known as CEMIPLIMAB-RWLC is used for for treatment of Advanced Cutaneous Squamous Cell Carcinoma



The tumour-reducing drug is aimed at patients with the second most common form of skin cancer—cutaneous squamous cell carcinoma (CSCC)—whose cancer is advanced, and who are not candidates for surgery or radiation therapy.

Confirming the conditional approval, the agency added in a statement that it had "adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Libtayo, intended for the treatment of advanced cutaneous squamous cell carcinoma".

"The benefits with Libtayo are its ability to reduce tumour size and to prevent progression of the tumour for longer," it said.
No drugs for the treatment of CSCC are currently approved in the EU, according to Sanofi.

Final approval of the drug will be given subject to Sanofi providing further results from clinical trials.

The US Food and Drug Administration (FDA) approved Libtayo in September 2018 while Health Canada gave it the conditional green light earlier this month.
 

MOST READ

Dec 31, 2025  2 days ago
Nikhil Prasad
Dec 30, 2025  3 days ago
Nikhil Prasad
Dec 27, 2025  6 days ago
Nikhil Prasad
Dec 25, 2025  8 days ago
Nikhil Prasad
Dec 24, 2025  9 days ago
Nikhil Prasad
Dec 22, 2025  11 days ago
Nikhil Prasad
Dec 21, 2025  12 days ago
Nikhil Prasad
Dec 15, 2025  18 days ago
Nikhil Prasad
Dec 11, 2025  22 days ago
Nikhil Prasad
Dec 10, 2025  23 days ago
Nikhil Prasad
Dec 09, 2025  24 days ago
Nikhil Prasad
Dec 07, 2025  26 days ago
Nikhil Prasad